Suppr超能文献

用于克服癌细胞多药耐药性的氧化还原响应性核交联嵌段共聚物胶束

Redox-Responsive Core-Cross-Linked Block Copolymer Micelles for Overcoming Multidrug Resistance in Cancer Cells.

机构信息

Department of Chemistry and ‡School of Medical Science and Technology, Indian Institute of Technology Kharagpur , Kharagpur, West Bengal 721302, India.

出版信息

ACS Appl Mater Interfaces. 2018 Feb 14;10(6):5318-5330. doi: 10.1021/acsami.7b18245. Epub 2018 Feb 5.

Abstract

Success of chemotherapy as a treatment for cancer has been often inhibited by multidrug resistance (MDR) of the cancer cells. There is a clear need to generate strategies to overcome this resistance. In this work, we have developed redox-responsive and core-cross-linked micellar nanocarriers using poly(ethylene glycol)-block-poly(2-(methacryloyloxy)ethyl 5-(1,2-dithiolan-3-yl)pentanoate) diblock copolymers (PEG-b-PLAHEMA) with tunable swelling properties for the delivery of drugs toward drug-sensitive MDA-MB-231 and drug-resistant MDA-MB-231 (231R) cancer cells. PEG-b-PLAHEMA containing varying number of 2-(methacryloyloxy)ethyl 5-(1,2-dithiolan-3-yl)pentanoate (LAHEMA) units were synthesized by employing the reversible addition-fragmentation chain transfer polymerization technique. The block copolymer self-assembly, cross-linking induced by reduction, and de-cross-linking triggered time-dependent controlled swelling of micelles were studied using dynamic light scattering, fluorescence spectroscopy, and transmission electron microscopy. In vitro cytotoxicity, cellular uptake efficiency, and glutathione-responsive anticancer activity of doxorubicin (DOX) encapsulated in core-cross-linked block copolymer micelles (CCMs) toward both drug-sensitive and drug-resistant cancer cell lines were evaluated. Significant reduction in IC was observed by DOX-loaded CCMs toward drug-resistant 231R cancer cell lines, which was further improved by coencapsulating DOX and verapamil (a P-glycoprotein inhibitor) in CCMs. Thus, these reduction-sensitive biocompatible CCMs with tunable swelling property are very promising in overcoming MDR in cancer cells.

摘要

化疗作为癌症治疗方法的成功率经常受到癌细胞的多药耐药性(MDR)的抑制。显然需要生成克服这种耐药性的策略。在这项工作中,我们使用聚乙二醇-嵌段-聚(2-(甲基丙烯酰氧基)乙基 5-(1,2-二硫戊环-3-基)戊酸酯)嵌段共聚物(PEG-b-PLAHEMA),开发了具有可调节溶胀性能的氧化还原响应性和核交联胶束纳米载体,用于将药物递送至对药物敏感的 MDA-MB-231 和耐药的 MDA-MB-231(231R)癌细胞。通过使用可逆加成-断裂链转移聚合技术,合成了含有不同数量 2-(甲基丙烯酰氧基)乙基 5-(1,2-二硫戊环-3-基)戊酸酯(LAHEMA)单元的 PEG-b-PLAHEMA。使用动态光散射、荧光光谱和透射电子显微镜研究了嵌段共聚物的自组装、还原诱导的交联以及胶束的时间依赖性控制溶胀的脱交联。评估了载有阿霉素(DOX)的核交联嵌段共聚物胶束(CCMs)对两种药物敏感和耐药癌细胞系的体外细胞毒性、细胞摄取效率和谷胱甘肽响应性抗癌活性。DOX 负载的 CCMs 对耐药 231R 癌细胞系的 IC 显著降低,通过共包封 DOX 和维拉帕米(一种 P-糖蛋白抑制剂)在 CCMs 中进一步提高了这种降低。因此,这些具有可调节溶胀性能的还原敏感生物相容性 CCMs 在克服癌细胞的多药耐药性方面具有很大的应用前景。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验